Skip to main content
SpringerLink
Log in

Trastuzumab biosimilar cost saving in Croatia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Cesarec A, et al. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia. Applied Health Economics and Health Policy : 11 Oct 2016. Available from: URL: http://dx.doi.org/10.1007/s40258-016-0285-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trastuzumab biosimilar cost saving in Croatia. PharmacoEcon Outcomes News 764, 33 (2016). https://doi.org/10.1007/s40274-016-3482-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3482-6

Search

Navigation